natgillin/translations-raw huggingface dataset:
With regard to safety, the Committee considered that the potential for allergic reactions and the development of antibodies against the medicine is expected, and is outweighed by the beneficial effects. 
Glede varnosti je menil, da sta možnost alergijskih reakcij in razvoj protiteles proti zdravilu pričakovana, a ju koristni učinki zdravila odtehtajo.
As a result, it will not be as easily recognised by the antibodies and it can replace the human factor VIII that has been inactivated, thereby helping the blood to clot and controlling the bleeding. 
Posledično jo protitelesa ne prepoznajo tako zlahka, zato lahko nadomesti humani faktor VIII, ki je bil deaktiviran, ter tako pomaga pri strjevanju krvi in nadzoru nad krvavitvijo.
This is because it has not been possible to obtain complete information about Obizur due to the rarity of the disease. 
Do tega je prišlo zato, ker zaradi redkosti bolezni ni bilo mogoče pridobiti vseh informacij o njem.
Since Obizur has been approved under exceptional circumstances, the company that markets the medicine will establish and maintain a patient registry to collect and analyse short- and long-term data on the effectiveness and safety of Obizur in patients with acquired haemophilia caused by antibodies against factor VIII. 
Ker je zdravilo Obizur pridobilo dovoljenje za promet v izjemnih okoliščinah, bo družba, ki ga trži, vzpostavila in vzdrževala register bolnikov, v katerem bo zbirala in analizirala kratkoročne in dolgoročne podatke o učinkovitosti in varnosti zdravila Obizur pri bolnikih s pridobljeno hemofilijo, ki jo povzročajo protitelesa proti faktorju VIII.
It is not intended to provide practical advice on how to use Obizur. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
A risk management plan has been developed to ensure that Obizur is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Obizur je bil pripravljen načrt obvladovanja tveganj.
susoctocog alfa, works in the body in the same way as human factor VIII, but has a slightly different shape. 
Zdravilna učinkovina v zdravilu Obizur, susoktokog alfa, deluje v telesu enako kot humani faktor VIII, vendar ima nekoliko drugačno obliko.
What are the risks associated with Obizur? 
Kakšna tveganja so povezana z zdravilom Obizur ?
What is Obizur and what is it used for? 
Kaj je zdravilo Obizur in za kaj se uporablja?
The results of the main study showed that Obizur was effective in treating serious bleeding episodes in adults with the disorder. 
Rezultati glavne študije so pokazali, da je bilo zdravilo Obizur učinkovito pri zdravljenju resnih epizod krvavitev pri odraslih s to motnjo.
This is a summary of the European public assessment report (EPAR) for Obizur. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Obizur.
Additionally, the company that markets Obizur will provide healthcare professionals who are expected to use Obizur with educational material containing information on how to calculate the dose. 
Poleg tega bo družba, ki trži zdravilo Obizur, zdravstvenim delavcem, za katere se pričakuje, da ga bodo uporabljali, priskrbela izobraževalno gradivo, ki bo vsebovalo informacije o izračunu odmerkov.
Obizur must not be used in patients who have had a severe allergic reaction to susoctocog alfa, any of its other ingredients, or hamster protein. 
Zdravila Obizur ne smejo uporabljati bolniki, ki so imeli hudo alergijsko reakcijo na susoktokog alfa ali katero koli drugo sestavino zdravila ali na beljakovine hrčka.
Obizur can only be obtained with a prescription and treatment should be supervised by a doctor with experience in the treatment of haemophilia. 
Izdaja zdravila Obizur je le na recept, zdravljenje pa mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem hemofilije.
Patients with acquired haemophilia caused by antibodies against factor VIII have blood clotting problems, such as bleeding in the joints, muscles or internal organs. 
Bolniki s pridobljeno hemofilijo, ki jo povzročajo protitelesa proti faktorju VIII, imajo zaplete s strjevanjem krvi, kot so krvavitve v sklepe, mišice ali notranje organe.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Obizur, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For more information about treatment with Obizur, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Obizur preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What information is still awaited for Obizur? 
Katere informacije o zdravilu Obizur še pričakujemo?
Obizur is available as a powder and solvent that are mixed together to make a solution for injection into a vein. 
Zdravilo Obizur je na voljo v obliki praška in vehikla, ki se zmešata za pripravo raztopine za injiciranje v veno.
Obizur contains the active substance susoctocog alfa. 
Zdravilo Obizur vsebuje zdravilno učinkovino susoktokog alfa.
For practical information about using Obizur, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Obizur naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Other information about Obizur 
Druge informacije o zdravilu Obizur
How is Obizur used? 
Kako se zdravilo Obizur uporablja?
Obizur has been investigated in one main study involving 28 adult patients with acquired haemophilia caused by antibodies against factor VIII who were experiencing a serious bleeding episode. 
Zdravilo Obizur so proučevali v eni glavni študiji, ki je vključevala 28 odraslih bolnikov s pridobljeno hemofilijo, ki so jo povzročila protitelesa proti faktorju VIII, ter z resno epizodo krvavitve.
Patients with acquired haemophilia caused by antibodies against factor VIII may develop antibodies against susoctocog alfa. 
Pri bolnikih s pridobljeno hemofilijo, ki jo povzročajo protitelesa proti faktorju VIII, se lahko razvijejo protitelesa proti susoktokogu alfa.
For the full list of all side effects and restrictions with Obizur, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Obizur glejte navodilo za uporabo.
The CHMP noted the lack of specific treatments for acquired haemophilia caused by antibodies against factor VIII. 
Odbor je upošteval pomanjkanje določenih zdravil za zdravljenje pridobljene hemofilije, ki jo povzročajo protitelesa proti faktorju VIII.
Obizur is a medicine used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII. 
Obizur je zdravilo, ki se uporablja za zdravljenje epizod krvavitev pri odraslih s pridobljeno hemofilijo, tj. motnjo strjevanja krvi, ki jo povzroča spontani razvoj protiteles, ki deaktivirajo faktor VIII.
How does Obizur work? 
Kako zdravilo Obizur deluje?
--1 Recombinant Protein Q from Leishmania infantum MON-1 ≥ 36.7 ELISA Units (EU)* * Antigen content determined in an ELISA against an internal standard. 
Rekombinantni protein Q iz parazita Leishmania infantum MON-1 ≥ 36,7 enot ELISA (EU)* * Vsebnost antigena je določena s testom ELISA v primerjavi z internim standardom.
EU (MA) Number Invented name 
EU (MA) številka Izmišljeno ime
Lyophilisate: 1 vial; solvent: 
Karenca liofilizat: 1 viala; vehikel: 1 viala liofilizat: 4 viale; vehikel: 4 viale liofilizat: 100 vial; vehikel:
Packaging Content 
Pakiranje Vsebina
Subcutaneous use Vial (glass) 
Subkutana uporaba viala (steklo)
10 mg/ ml Solution for injection. 
INCRELEX 10 mg/ml Raztopina za injiciranje
1 Vial 
1 viala
Strength Pharmaceutical Form 
Izmišljeno ime Jakost farmacevtska oblika pot uporabe
Package size 
Ovojnina vsebina velikost pakiranja
This summary was last updated in 10-2011. 
Povzetek je bil nazadnje posodobljen 10-2011.
Similar results were seen in the second study. 
Podobni rezultati so bili ugotovljeni tudi v drugi študiji.
Other information about Aerinaze 
Druge informacije o zdravilu Aerinaze
The European Commission granted a marketing authorisation valid throughout the European Union for Aerinaze on 30 July 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Aerinaze, veljavno po vsej Evropski uniji, odobrila dne 30. julija 2007.
The effectiveness of Aerinaze was assessed in two main studies involving a total of 1,248 adult and adolescent patients. 
Učinkovitost zdravila Aerinaze so proučevali v dveh glavnih študijah s skupno 1 248 odraslimi in mladostniki.
The full EPAR for Aerinaze can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Aerinaze je na voljo na spletni strani agencije: : ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What benefit has Aerinaze shown during the studies? 
Kakšne koristi je zdravilo Aerinaze izkazalo med študijami?
In adults and adolescents over 12 years of age, the recommended dose of Aerinaze is one tablet twice a day, taken whole with a full glass of water. 
Pri odraslih in mladostnikih, starejših od 12 let, je priporočeni odmerek zdravila Aerinaze ena tableta dvakrat dnevno, ki jo je treba pogoltniti celo s polnim kozarcem vode.
This is a summary of the European public assessment report (EPAR) for Aerinaze. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aerinaze.
It is available as blue and white modified-release tablets. 
Na voljo je v obliki modrih in belih tablet s prirejenim sproščanjem.
The main measures of effectiveness were the change in the severity of hayfever symptoms reported by the patients between before treatment started, and over the entire 15 days of treatment. 
Glavno merilo učinkovitosti je bila sprememba resnosti simptomov senenega nahoda, o katerih so bolniki poročali pred začetkom zdravljenja in v celotnem 15-dnevnem obdobju zdravljenja.
For more information about treatment with Aerinaze, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Aerinaze preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Treatment should continue for as short a time as possible and should stop when symptoms, chiefly the congestion (blocked nose), have disappeared. 
Zdravljenje naj bo čim krajše in ga je treba ustaviti, kakor hitro simptomi, zlasti kongestija (zamašen nos), izginejo.
It should not be used in people who are taking a monoamine oxidase inhibitor (such as some medicines used to treat depression) or who have stopped taking one of these medicines within the last two weeks. 
Ne smejo ga uporabljati osebe, ki se zdravijo z zaviralci monoaminooksidaze (na primer z nekaterimi zdravili za zdravljenje depresije) ali ki so v zadnjih dveh tednih prenehale jemati katero izmed teh zdravil.
What is the risk associated with Aerinaze? 
Kakšna tveganja so povezana z zdravilom Aerinaze?
When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy. 
Če so receptorji blokirani, histamin ne more učinkovati, zaradi česar se zmanjšajo simptomi alergije.
The patients recorded their symptoms in a diary every 12 hours during the study, scoring on a standard symptom scale how severe the symptoms were over the previous 12-hour period. 
Bolniki so med študijo beležili simptome v dnevnik vsakih 12 ur in ocenjevali njihovo resnost v preteklem 12-urnem obdobju s pomočjo standardne lestvice za ocenjevanje simptomov.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aerinaze. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Aerinaze, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
This reduces the amount of fluid released from the vessels, resulting in less swelling and less mucus production in the nose. 
To zmanjša količino tekočine, ki se sprošča iz žil, kar vodi do zmanjšanja otekanja in nastajanja sluzi v nosu.
Desloratadine is released from its layer immediately after it is taken, while pseudoephedrine is released slowly over 12 hours. 
Desloratadin se iz svoje plasti začne sproščati takoj po zaužitju tablete, medtem ko se psevdoefedrin sprošča počasi v obdobju 12 ur.
Why has Aerinaze been approved? 
Zakaj je bilo zdravilo Aerinaze odobreno?
Aerinaze is a medicine containing the active substances desloratadine (2.5 mg) and pseudoephedrine (120 mg). 
Aerinaze je zdravilo, ki vsebuje zdravilni učinkovini desloratadin (2,5 mg) in psevdoefedrin (120 mg).
When looking at nasal congestion, patients taking Aerinaze had a reduction in symptoms of 37.4%, compared with 26.7% in those taking desloratadine alone. 
Z vidika obravnave kongestije nosne sluznice so se pri bolnikih, ki so jemali zdravilo Aerinaze, simptomi zmanjšali za 37,4 %, pri bolnikih, ki so jemali samo desloratadin, pa za 26,7 %.
‘Modified-release' means that the tablets have been made to allow one of the active substances to be released immediately and the other one released over a few hours. 
Prirejeno sproščanje pomeni, da so tablete izdelane tako, da omogočajo sprostitev ene zdravilne učinkovine takoj, druga pa se sprošča več ur.
When looking at all hayfever symptoms except for nasal congestion, patients taking Aerinaze reported a reduction in symptoms of 46.0%, compared with 35.9% in those taking pseudoephedrine alone. 
Z vidika obravnave vseh simptomov senenega nahoda z izjemo kongestije nosne sluznice so bolniki, ki so jemali zdravilo Aerinaze, poročali o zmanjšanju simptomov za 46,0 %, v primerjavi z zmanjšanjem za 35,9 % pri bolnikih, ki so jemali samo psevdoefedrin.
Aerinaze was more effective in reducing symptoms than either of the two active substances taken alone. 
Zdravilo Aerinaze je bilo pri zmanjševanju simptomov učinkovitejše od obeh zdravilnih učinkovin, uporabljenih samostojno.
For the full list of all side effects reported with Aerinaze, see the Package Leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Aerinaze, glejte navodilo za uporabo.
Desloratadine/pseudoephedrine 
Povzetek EPAR za javnost desloratadin/psevdoefedrin
In Aerinaze, the two active substances are used together, since an antihistamine alone may not provide adequate relief for patients with nasal congestion. 
V zdravilu Aerinaze sta obe zdravilni učinkovini uporabljeni v kombinaciji, saj sam antihistaminik ne bi zagotovil ustreznega olajšanja pri bolnikih s kongestijo nosne sluznice.
The most common side effects with Aerinaze (seen in between 1 and 10 patients in 100) are tachycardia (fast heart rate), dry mouth, dizziness, psychomotor hyperactivity (restlessness), pharyngitis (sore throat), anorexia (loss of appetite), constipation, headache, fatigue (tiredness), insomnia (difficulty sleeping), somnolence (sleepiness), sleep disorders and nervousness. 
Najpogostejši neželeni učinki zdravila Aerinaze (opaženi pri 1 do 10 bolnikih od 100) so tahikardija (pospešeno bitje srca), suha usta, omotica, psihomotorična hiperaktivnost (nemirnost), faringitis (vneto žrelo), anoreksija (izguba teka), zaprtje, glavobol, utrujenost, nespečnost, zaspanost, motnje spanja in živčnost.
Desloratadine has been available in the European Union (EU) since 2001, and pseudoephedrine is widely used in medicines that have been available over-the-counter for many years. 
To pomeni, da morajo bolniki tableto vzeti samo dvakrat na dan. Desloratadin je na voljo v Evropski uniji (EU) od leta 2001, psevdoefedrin pa se že vrsto let pogosto uporablja v zdravilih, ki se izdajajo brez recepta.
The Committee for Medicinal Products for Human Use (CHMP) decided that Aerinaze's benefits are greater than its risks for the symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion and recommended that Aerinaze be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Aerinaze pri simptomatskem zdravljenju sezonskega alergijskega rinitisa, ki ga spremlja kongestija nosne sluznice, večje od z njim povezanih tveganj in priporočil, da se zanj odobri dovoljenje za promet z zdravilom.
Pseudoephedrine works by stimulating nerve endings to release the chemical noradrenaline, which causes the blood vessels to constrict (narrow). 
Psevdoefedrin spodbuja živčne končiče, da sproščajo kemijsko snov noradrenalin, ki povzroča zožitev krvnih žil.
Aerinaze must not be used in people who are hypersensitive (allergic) to desloratadine, pseudoephedrine or any of the other ingredients, to adrenergic agents or to loratadine (another medicine used to treat allergies). 
Zdravila Aerinaze ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) desloratadin, psevdoefedrin ali katero koli drugo sestavino zdravila, adrenergične učinkovine ali loratadin (drugo zdravilo za zdravljenje alergij).
Aerinaze should also not be taken by people who have narrow angle glaucoma (increased pressure inside the eye), urinary retention (difficulty in passing urine), heart or blood vessel diseases including hypertension (high blood pressure), hyperthyroidism (an overactive thyroid gland), or a history or risk of haemorrhagic stroke (stroke caused by bleeding within the brain). 
Prav tako zdravila Aerinaze ne smejo jemati osebe, ki imajo glavkom ozkega zakotja (povečan tlak v notranjosti očesa), zastoj seča (težave pri izločanju seča), srčnožilne bolezni, vključno s hipertenzijo (visokim krvnim tlakom), hipertiroidizem (povečano delovanje ščitnice) ali anamnezo oziroma tveganje za hemoragično možgansko kap (kap zaradi krvavitve v možganih).
Desloratadine works by blocking the receptors on which histamine, a substance in the body that causes allergic symptoms, normally attaches itself. 
Desloratadin deluje kot zaviralec receptorjev, na katere se običajno veže histamin, tj. snov v telesu, ki povzroča alergijske simptome.
Aerinaze tablets have two layers, one containing desloratadine, and the other containing pseudoephedrine. 
Tablete zdravila Aerinaze so dvoplastne, ena plast vsebuje desloratadin, druga pa psevdoefedrin.
What is Aerinaze? 
Kaj je zdravilo Aerinaze?
Aerinaze is used to treat the symptoms of seasonal allergic rhinitis (hayfever, inflammation of the nasal passages caused by an allergy to pollen) in patients who have nasal congestion (a blocked nose). 
Zdravilo Aerinaze se uporablja za zdravljenje simptomov sezonskega alergijskega rinitisa (senenega nahoda, vnetja nosnih poti zaradi preobčutljivosti na cvetni prah) pri bolnikih s kongestijo nosne sluznice (zamašenim nosom).
In both studies, Aerinaze was compared with desloratadine alone and with pseudoephedrine alone. 
V obeh študijah so zdravilo Aerinaze primerjali z desloratadinom kot samostojnim zdravilom in psevdoefedrinom kot samostojnim zdravilom.
What is Aerinaze used for? 
Za kaj se zdravilo Aerinaze uporablja?
Treatment for more than 10 days is not advisable, as the medicine's effects on nasal congestion may wear off. Once the nose has cleared, patients can use desloratadine alone. 
Zdravljenje, daljše od 10 dni, ni priporočljivo, saj učinek zdravila na kongestijo nosne sluznice sčasoma pojenja.
Aerinaze contains two active substances: desloratadine, an antihistamine, and pseudoephedrine, which is a nasal decongestant. 
Zdravilo Aerinaze vsebuje dve zdravilni učinkovini: desloratadin, ki je antihistaminik, in psevdoefedrin, ki je nosni dekongestiv.
How has Aerinaze been studied? 
Kako je bilo zdravilo Aerinaze raziskano?
How does Aerinaze work? 
Kako zdravilo Aerinaze deluje?
How is Aerinaze used? 
Kako se zdravilo Aerinaze uporablja?
Date of first authorisation: 25 July 2013. 
Datum prve odobritve: 25. julij 2013.
There is no evidence that such an interaction would be harmful. 
Ni dokazov, da bi bilo tako medsebojno delovanje škodljivo.
Find a comfortable, well-lit place. 
Najdite udobno, dobro osvetljeno mesto.
*This is based on protein content only. 
*To temelji le na vsebnosti beljakovine.
This could damage the safety device. 
To bi lahko poškodovalo varnostni pripomoček.
The safety device will be activated immediately. 
Varnostni pripomoček se takoj aktivira.
The relevance of these findings for humans is not known. 
Pomen teh ugotovitev za človeka ni znan.
Proper treatment of your disease, however, requires close and constant co-operation with your doctor. 
Pravilno zdravljenje vaše bolezni zahteva tesno in stalno sodelovanje z vašim zdravnikom.
CI = confidence interval 
IZ = interval zaupanja
Healthy volunteers 
Zdravi prostovoljci
The results of the study are presented in table 3. 
Rezultati študije so predstavljeni v preglednici 3.
Date of latest renewal: 08 May 2018 
Datum zadnjega podaljšanja: 08. maj 2018.
This antibody response can, in some cases, lead to undesirable effects or loss of efficacy. 
Ta protitelesni odziv lahko v nekaterih primerih povzroči neželene učinke ali izgubo učinkovitosti.
This should be considered when interpreting bone-imaging results. 
To je treba upoštevati pri razlagi rezultatov slikanja kosti.
Incidence (%) 
Incidenca (%)
The incidence of FN varied according to age (from 14.3 % to 71.4 %), with the highest frequency in the oldest age group. 
Incidenca FN se je glede na starost razlikovala (od 14,3 % do 71,4 %), pri čemer je bila največja pogostnost v najstarejši starostni skupini.
Your doctor will carry out regular blood tests in order to monitor various blood components and their levels. 
Vaš zdravnik bo z rednimi krvnimi preiskavami zagotavljal nadzor nad različnimi sestavinami krvi in njihovimi ravnmi.
Do not give this medicine to children and adolescents under 18 years of age because there is only limited experience in children to show that this medicine is safe and works in this age group. 
Tega zdravila ne dajajte otrokom in mladostnikom, starim manj kot 18 let, saj so izkušnje pri otrocih, ki bi dokazale, da je to zdravilo varno in da deluje v tej starostni skupini, omejene.
The first injection should be performed under direct medical supervision. 
Prvo injiciranje je treba izvesti pod neposrednim zdravniškim nadzorom.
Frequency groupings are defined according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Skupine pogostnosti so opredeljene v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The mean terminal half-lives in the fourth cycle were approximately 39 and 42 hours. 
Povprečna končna razpolovna časa v četrtem ciklu sta bila približno 39 in 42 ur.
Nevertheless, pharmacodynamic effects were similar and independent from gender and injection site. 
Kljub temu pa so bili farmakodinamični učinki podobni in neodvisni od spola in mesta injiciranja.
If there are particles in it or if it is cloudy, you must not use it. 
Če so v njej delci ali je motna, je ne smete uporabiti.
Do not use this medicine if you notice that it is cloudy or there are particles in it. 
Ne uporabljajte tega zdravila, če opazite, da je motno ali da so v njem delci.
Do not warm Lonquex in any other way (for example, do not warm it in a microwave or in hot water). 
Zdravila Lonquex ne smete ogrevati na kak drug način (ne ogrevajte ga na primer v mikrovalovni pečici ali v vroči vodi).
If a patient fails to respond to treatment, the patient should undergo further evaluation. 
Če se bolnik na zdravljenje ne odzove, ga je treba dodatno oceniti.